Press release
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing and commercializing therapeutics targeting rare central nervous system (CNS) and neurodegenerative conditions;Advancing development of KP1077, a serdexmethylphenidate (SDX) based product candidate for idiopathic hypersomnia (IH), as KemPharm’s lead candidate: Pre-Investigational New Drug (IND) process with the U.S. Food and Drug Administration (FDA) successfully completed in February 2022;IND filing expected as early as the second quarter of 2022; Phase 2 trial initiation expected in the second half of 2022; andReported data from the Phase 1 clinical trial exploring the safety and pharmacokinetics (PK) of “higher-dose” SDX which validates selection of KP1077 as lead product candidate. AZSTARYS® national launch accelerating; full national sales team in place as of January 31, 2022, growing payor access;KemPharm named 2021 David J. Gury Company of the Year by BioFlorida; andEarned $1.975 million fee in first quarter of 2022 following FDA approval of Corium, Inc.’s product, ADLARITY®. Financial Highlights Reported quarter ended December 31, 2021 (Q4 2021) revenue of $2.6 million and FY 2021 revenue of $28.7 million; andTotal cash, cash equivalents and long-term investments was $127.8 million as of December 31, 2021. CELEBRATION, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today reported its financial results for the fourth quarter and year ended December 31, 2021. “KemPharm advanced on multiple fronts during the fourth quarter of 2021 and into early 2022, cementing the past twelve months as the most substantial in KemPharm’s history,” stated Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm. “In January, we announced our strategic focus on developing and commercializing therapeutics targeting rare CNS and neurodegenerative conditions starting with KP1077. The data released earlier this month from the Phase 1 clinical trial exploring the safety and PK of ‘higher dose SDX,’ affirms the opportunity to develop multiple SDX-based dr...